Analysis of Global Status of Research, Development and Market on Stem Cell

PDF(675 KB)

China Biotechnology ›› 2011, Vol. 31 ›› Issue (9) : 132-139.

FU Jun-ying

Author information +

History +

Abstract

Stem cell has become the global focus for its promising potential in research and practice. The governments, Institutes and enterprises all over the world have been increasing investment, and have made great progresses. Stem cell related papers and patents have sharply going up since 2001, and researches on clinic and pre-clinic trials became more and more though majority still focus on umbilical cord blood stem cells. USA remains the top position in all aspects in stem cell field. The numbers of stem cell related papers and patents produced by China are ranking top 10 around the world, but no Institute belongs to top one, and not many new products are developed successfully. China has to learn how to actively react to the changes resulted from related looser policy in USA.

Key words

Stem cell / Research / Development / Market

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

FU Jun-ying. Analysis of Global Status of Research, Development and Market on Stem Cell[J]. China Biotechnology, 2011, 31(9): 132-139

References

[1] Al-Tanbal H, Al Humaidan H, Al-Nounou R, et al. The value and practicality of granulocyte transfusion: a single oncology centre experience. Transfusion Medicine, 2010, 20(3): 160-168.

[2] 《中国组织工程研究与临床康复》杂志社学术部. 让昨天告诉今天:干细胞研究的学术与技术进展.中国组织工程研究与临床康复, 2009,13(6): 1102-1103. Academic Committee of Journal of Clinical Rehabilitative Tissue Engineering Research. Journal of Clinical Rehabilitative Tissue Engineering Research, 2009,13(6): 1102-1103.

[3] 石磊. 人类胚胎干细胞研究再起争议.世界科学, 2010,(10): 28-29. Shi L. World science, 2010,(10): 28-29.

[4] 朱宛宛,于洋,周琪.国际新格局下的干细胞研究发展与展望.学科发展,2009,24(3):284-289. Zhu W W, Yu Y, Zhou Q. Disciplinary Development, 2009,24(3):284-289.

[5] 李建明曾华锋. 论科技政策背后的利益主体——以美国胚胎干细胞研究为例. 自然辩证法通讯, 2010,(5): 60-65. Li J W, Zeng H F. Journal of Dialectics of Nature, 2010,(5): 60-65.

[6] 江洪波,陈大明,于建荣.世界各国干细胞治疗相关政策与规划分析.生物产业技术,2009,(1):11-18. Jiang H B, Chen D M, Yu J R. Biotechnology & Business, 2009,(1):11-18.

[7] 李国炜,陈碧渊. 德国"干细胞法"及其述评. 医学与哲学, 2004,25(7): 76-77. Li G W, Chen B Y. Medicine & Philosophy, 2004,25(7): 76-77.

[8] Brian S,Melinda C,Amanda D,等. 英中印三国的干细胞战略. 生物技术世界, 2007,(2): 78-83. Brian S,Melinda C,Amanda D,et al. Biotechworld, 2007,(2): 78-83.

[9] 王静波.韩国生物技术的发展及其启示. 生物技术世界, 2006(2): 7-15. Wang J B. Biotechworld, 2006(2): 7-15.

[10] GBI Research. Stem Cell Research-Market Trends, Investment Trends and Pipeline Analysis. 2010.

[11] Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nature Biotechnology, 2010, 28(10): 989-990.